CN117580590A - 用于抑制艰难梭菌的增殖的含有单克隆抗体的组合物 - Google Patents

用于抑制艰难梭菌的增殖的含有单克隆抗体的组合物 Download PDF

Info

Publication number
CN117580590A
CN117580590A CN202280046164.0A CN202280046164A CN117580590A CN 117580590 A CN117580590 A CN 117580590A CN 202280046164 A CN202280046164 A CN 202280046164A CN 117580590 A CN117580590 A CN 117580590A
Authority
CN
China
Prior art keywords
amino acid
ser
acid sequence
thr
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280046164.0A
Other languages
English (en)
Chinese (zh)
Inventor
新藏礼子
森田直树
玉野竜太郎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tokyo NUC
Original Assignee
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tokyo NUC filed Critical University of Tokyo NUC
Publication of CN117580590A publication Critical patent/CN117580590A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN202280046164.0A 2021-07-02 2022-06-30 用于抑制艰难梭菌的增殖的含有单克隆抗体的组合物 Pending CN117580590A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021-110423 2021-07-02
JP2021110423 2021-07-02
PCT/JP2022/026399 WO2023277166A1 (ja) 2021-07-02 2022-06-30 クロストリジウム・ディフィシル菌の増殖を抑制するためのモノクローナル抗体含有組成物

Publications (1)

Publication Number Publication Date
CN117580590A true CN117580590A (zh) 2024-02-20

Family

ID=84692754

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280046164.0A Pending CN117580590A (zh) 2021-07-02 2022-06-30 用于抑制艰难梭菌的增殖的含有单克隆抗体的组合物

Country Status (7)

Country Link
US (1) US20240417450A1 (https=)
EP (1) EP4364755A4 (https=)
JP (2) JP7430946B2 (https=)
KR (1) KR20240026998A (https=)
CN (1) CN117580590A (https=)
CA (1) CA3224499A1 (https=)
WO (1) WO2023277166A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240082370A (ko) * 2021-09-30 2024-06-10 이구아루판 가부시키가이샤 모노클로널 항체 함유 조성물
TW202440928A (zh) 2023-03-03 2024-10-16 國立大學法人東京大學 免疫球蛋白
CN121127591A (zh) * 2023-05-12 2025-12-12 国立大学法人东京大学 与艰难梭菌结合的抗体
WO2025220732A1 (ja) * 2024-04-17 2025-10-23 国立研究開発法人国立循環器病研究センター 肺高血圧症の予防又は治療薬

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090087478A1 (en) * 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
US20110020356A1 (en) * 2007-12-07 2011-01-27 Lin Fang Therapeutic clostridium difficile antibody compositions
PT2411410E (pt) * 2009-03-27 2015-10-09 Gojo Ind Inc Composições e métodos para screening e utilização de compostos que antagonizam interações esporo-superfície
AR086199A1 (es) * 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
US9815889B2 (en) * 2011-08-02 2017-11-14 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Antibodies for prevention and treatment of diseases caused by clostridium difficile
JP5916946B2 (ja) 2013-03-11 2016-05-11 学校法人関西文理総合学園 モノクローナルＩｇＡ抗体の製造方法
JP2017001987A (ja) * 2015-06-11 2017-01-05 学校法人関西文理総合学園 ポリペプチド

Also Published As

Publication number Publication date
KR20240026998A (ko) 2024-02-29
EP4364755A1 (en) 2024-05-08
CA3224499A1 (en) 2023-01-05
JPWO2023277166A1 (https=) 2023-01-05
JP2024046661A (ja) 2024-04-03
US20240417450A1 (en) 2024-12-19
WO2023277166A1 (ja) 2023-01-05
JP7430946B2 (ja) 2024-02-14
EP4364755A4 (en) 2026-02-18

Similar Documents

Publication Publication Date Title
CN109790218B (zh) 抗tim-3抗体及其用途
KR102924276B1 (ko) 항-pd-1/vegfa 이기능성 항체, 이의 약제학적 조성물 및 이의 용도
CN117580590A (zh) 用于抑制艰难梭菌的增殖的含有单克隆抗体的组合物
KR20240026999A (ko) 클로스트리듐ㆍ디피실균에 결합하는 항체
KR101683033B1 (ko) 톨-유사 수용체 3 길항제
CN112673023A (zh) 抗SIRPα抗体
EP3712170A1 (en) Cd96 antibody, antigen-binding fragment and pharmaceutical use thereof
KR20180069071A (ko) Pd-1 및 tim-3과 특이적으로 결합하는 항체 및 그의 용도
CN114366818B (zh) 抗体药物偶联物及其应用
CN115956087B (zh) 抗-pd-1抗体
KR101758713B1 (ko) 톨-유사 수용체 3 길항제
CN114040924B (zh) 对lif具有特异性的结合分子及其用途
KR20230024408A (ko) 항-cldn-18.2 항체 및 그 용도
RU2829997C1 (ru) Антитело к cldn-18.2 и его применение
US20250051426A1 (en) Composition containing monoclonal antibody
RU2732155C1 (ru) Гуманизированное антитело или его антигенсвязывающий фрагмент (Fab) против шига-токсинов первого и/или второго типов (варианты), композиция для лечения токсических состояний, вызванных энтерогеморрагической кишечной палочкой, содержащая указанные антитела и/или Fab

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination